99 - Polycythemia Vera Flashcards

1
Q

What are the two groups of chronic myeloproliferative diseases?

A
  1. Myeloid phenotype

2. Megakaryocyte/erythroid hyperplasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the three myeloid phenotype causing myeloproliferative diseases?

A
  1. CML (myelocytic- BCR-ABL)
  2. CNL (neutrophilic)
  3. CEL (eosinophilic)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the three Megakaryocyte/erythroid hyperplasia causing myeloproliferative diseases?

A
  1. PV (polycythemia vera)
  2. ET (essential thrombocytosis)
  3. PMF (primary myelofibrosis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

PV frequency increases with ____, it has a slight ____ tendency, with ____ being more prominent in sporadic cases

A

Age
Familial
Female

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In ___ of patients we can find known chromosomal mutations such as ____ deletion or ____

A

30%
13q or 20q
9 trisomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

In ___ we can find ____ mutation where____ replaces ____

A

95%
JAK2
Phenylalanine
Valine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The mutation in JAK2 activates it without ___ dependency leading to an uncontrolled cell productio

A

EPO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Clinical features of PV include: (4)

A

Leukocytosis/Thrombocytosis
Splenomegaly
Thrombus (venous/arterial)
Aquagenic pruritus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hypervascular erythrocytosis may lead to the following symptoms: (2)

A
  1. Systolic HTN

2. Neurological symptoms (vertigo, headache, visual impairment, TIA, tinnitus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Thrombocytosis may lead to the following symptoms: (4)

A
  1. Thrombosis (cerebral, GI, hepatic vein)
  2. Acquired vWF
  3. Erythromelalgia
  4. Bleeding disorders (fingers ischemia, etc..)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the approach to diagnosing patients with PV?

A

*Increased hct/Hgb?
yes? continue

  • Measure RBC mass
    normal- Relative erythrocytosis
    elevated- continue

*Measure serum EPO levels-
low- PV- confirm with JAK2 mutation
elevated- continue

*Measure arterial O2 saturation
low- DD (COPD, high altitude, AV shunt…)
normal? continue

*Smoker?
no?- measure hemoglobin affinity-
increased- O2 affinity hemoglobinopathy
normal- search for tumors (renal US/CT)
yes?- Measure carboxyhemoglobin
elevated? Smokers polycythemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

In order to confirm absolute erythrocytosis by measuring _____. When unavailable and O2 saturation is normal- check for ____

A

RBC mass

JAK2 mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Normal EPO does not disclose ___, but high EPO suggests ____

A

PV

Secondary erythrocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the 3 situations leading to microcytic erythrocytosis (check RDW and MCV)?

A
  1. Beta thalassemia (normal RDW)
  2. Hypoxic erythrocytosis ( wide RDW)
  3. PV (wide RDW due to iron deficiency)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

___ examination has no value when trying to diagnose PV

A

BM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

The lack of ____ does not rule out PV

A

genetic marker

17
Q

What are the two mechanisms leading to PV complications?

A

Hyperviscosity- due to increased amount of cells

Increased cell turnover- increase in cytokines and uric acid

18
Q

_____ infection is more common in PV patients, which may lead to higher frequency of ____

A

H. Pylori

PUD

19
Q

Men with PV should aim for Hgb of ___ and hct of ___, in order to avoid thrombosis.

20
Q

Women with PV should aim for Hgb of ___ and hct of ___, in order to avoid thrombosis.

21
Q

What are the 3 main treatments of PV?

A
  1. Phlebotomy
  2. Anticoagulation
  3. Ruxolitinib
22
Q

In PV patients, phlebotomy is recommended once every ___ months

23
Q

If treating PV with anticoagulation, we must avoid ____ when ____ is not under control

A

Salicylates

RBC

24
Q

Ruxolitinib is ____, and is used in PV patients who also suffer from ___ or ____.

A

JAK2 inhibitor
Myelofibrosis
Myeloid metaplasia

25
Asymptomatic _____ (<10) does not require treatment, unless the patient is to be treated with ____. If so, treat with _____
Hyperuricemia Chemotherapy Allopurinol
26
How would you treat symptomatic splenomegaly?
1. IFN alpha (reduce JAK2 levels) | 2. PDE inhibitor/hydroxyurea
27
Why PDE inhibitor is preferred over hydroxyurea when treating PV with symptomatic splenomegaly?
PDE inhibitor is not toxic for the BM, and protects from thrombosis
28
If PV patient is resistant to hydroxyurea how will you continue?
Ruxolitinib
29
If PV patient is resistant to Ruxolitinib how will you continue?
Splenectomy
30
What is PMF?
Primary myelofibrosis is a clonal hematopoietic stem cell disorder associated with mutations in JAK2, MPL or CALR and characterized by marrow fibrosis, extramedullary hematopoiesis, and splenomegaly
31
___ are more likely to be diagnosed with PMF, usually in their ___decade of life
Men | 6th